M alaria remains a major health burden in many countries across Africa. For children developing severe and complicated Plasmodium falciparum malaria, case fatality on current treatment remains high (1) . Among the physiologic derangements associated with severe, life-threatening malaria, metabolic acidosis has emerged as a central feature, being widely recognized as the best independent predictor of death in both children and adults (2) (3) (4) (5) .The highest mortality occurs in children presenting in deep coma with metabolic acidosis (6, 7) . We have previously hypothesized that acidosis in severe malaria is due in part to impaired perfusion (or hypovolemia) (3, 8 -10) . Together with others, we have generated new clear evidence indicating that volume depletion contributes to the pathophysiology of severe malaria and that volume expansion, the usual treatment of hypovolemia, is safe and may improve outcome (3, 10) . Never-theless, there remains considerable debate over whether volume depletion contributes to the pathophysiology in children with severe malaria, with anxieties expressed that volume expansion may result in more harm than benefit (8, 11, 12) . Current World Health Organization guidelines are unclear regarding which fluid to give, the volume and rate of administration, and clinical assessment for the need for fluid (13, 14) .
In a series of trials we have established that fluid resuscitation with 5% human albumin solution (HAS) results in a lower mortality than either 0.9% saline or Gelofusine (a gelatin polymer) (3, 10, 15, 16) . The greatest benefit was seen in the high-risk group with acidosis and coma (10) . Since HAS is costly, difficult to generate locally, and potentially unsustainable in Africa, we aimed to generate clinical data that extend our experience with colloidal-based resuscitation fluids in a randomized controlled trial using two other less costly synthetic colloids, 6% Dextran 70 (herein referred to as Dextran) and 6% hydroxy-Objectives: A previous meta-analysis has shown a consistent survival benefit in children with severe malaria receiving human albumin solution compared to other resuscitation fluids. Human albumin solution is expensive and not readily available in Africa. We examined the safety and efficacy of the fluid resuscitation with two synthetic colloids, Dextran 70 and hydroxyethyl starch, to inform future trial design.
Design: An open-label randomized, controlled, phase II safety and efficacy trial.
Setting ethyl starch (HES 130/0.4) in children with severe malaria. The aim was to collect data on the safety and efficacy of these two colloids for treatment of shock.
MATERIALS AND METHODS

Participants
The study was conducted at the highdependency unit of Kilifi District Hospital, Kenya. Children of Ͼ6 months of age fulfilling our clinical definition of severe malaria (7) , that is, either impaired consciousness (prostration or coma, Blantyre Coma Score Յ2) (17) or respiratory distress (increased work of breathing) (7) , were screened for inclusion in the study. Children were eligible for inclusion if they had all of the following criteria: Plasmodium falciparum parasitemia, clinical features of severe malaria, and metabolic acidosis (a base deficit Ͼ8). Children with any of the following at admission were excluded: hemoglobin of Ͻ5 g/dL, pulmonary edema (defined as clinical evidence of the presence of fine crepitations in both lungs plus oxygen saturations of Ͻ90%); any condition that may contraindicate the use of volume replacement, for example, established renal failure, known congenital heart disease, clinical evidence of severe malnutrition (severe wasting and/or kwashiorkor); and children with decompensated shock (systolic blood pressure Ͻ70 mm Hg for children less than 1 yr old or Ͻ80 mm Hg if aged Ͼ1 yr). The participants in the trial were therefore comparable to study cohorts enrolled in our previous fluid resuscitation trials (3, 15, 18) , with one exception (16) . Children were recruited to the trial only if prior consent was obtained from parents or guardians, since ethical approval was not granted to defer consent in critically ill cases with decompensated shock.
Children eligible for the current trial were also eligible for an ongoing multicentered trial comparing intravenous artesunate versus quinine (AQUAMAT; ISRCTN: 50258054) and so were coenrolled into both the current trial and the AQUAMAT trial. Children whose parents refused consent were not enrolled into either trial. The trial, including coenrolment, was approved by the Kenya Medical Research Institute (KEMRI) National Ethics Committee, Nairobi, Kenya, in December 2005 and the Oxford Research Committee. Prospective informed consent was obtained from all parents/ guardians before enrolment. This trial was registered in September 2005 (ISRCTN: 35536139: URL http://controlled-trials.com/ ISRCTN35536139).
Interventions
Children received an initial bolus of the intervention fluid, Dextran or HES, of 20 mL/kg over 1 hr. At 1 hr after assessment, a further bolus of 20 mL/kg was given if features of shock persisted. Shock was defined as nonattainment of all the following resuscitation end points: heart rate within appropriate ranges for age, capillary refill time less than 3 secs, systolic blood pressure within threshold range for age (using a pragmatic cut off of Ն70 mm Hg for children less than 1 yr old or Ն80 mm Hg if aged Ͼ1 yr), and oxygen saturations of Ͼ95% in room air. Beyond 2 hrs, further boluses were given only for the development of decompensated shock (hypotension and any of the above clinical features of shock). Children were continuously monitored for blood pressure, electrocardiography, respiratory rate, oxygen saturation, and core temperature using a Siemens multichannel recorder. Children received antimalarial medication as specified in the AQUAMAT trial protocol. Otherwise, all other aspects of treatment were identical between the two groups (reported previously [18] ). Whole-blood transfusion (20 mL/kg) infused over the course of admission was reserved for cases whose hemoglobin fell below 4 g/dL (or to Ͻ5 g/dL if associated with deep "acidotic" breathing). Ventilation facilities are not available, but children with short-term apnea following convulsions were resuscitated with mask and bag manual ventilation.
Adverse events, serious adverse events, and serious unexpected events were reported to the local safety monitor and national ethics board on a case-by-case basis. Annual summaries of events were prepared for the data safety and monitoring committee. The trial was monitored twice by independent clinical trial monitors. The trial continued until completion, by which time 80 children had been recruited.
Objectives
To establish whether hypovolemic shock manifesting as acidosis in severe malaria can be safely corrected by volume replacement with Dextran (Gentran 70, Baxter Healthcare, United Kingdom: batch numbers 0SJ14BM and 07G03BX) or HES (Voluven, Fresenius Kabi, United Kingdom: batch numbers TIL196 00:31 and WDL18313:28). The other main objective was to assess the frequency of serious side effects, namely, pulmonary edema, suspected raised intracranial pressure, and allergic reaction. The null hypothesis was that there is no difference in the safety profile or effect on physiologic parameters of shock using starch or Dextran-based colloids for fluid resuscitation.
Outcomes
The primary end point was the resolution of shock in either arm, as determined by proportions attaining locally adapted American College of Critical Care Medicine/Pediatric Advanced Life Support therapeutic (resuscitation) end points (here called resuscitation targets) at 8 hrs (19, 20) . Attainment of resuscitation targets was defined as the absence of all of the following features: severe tachycardia (Ͼ180 beats/minute if aged Ͻ12 months, Ͼ160 beats/minute if aged 1-5 yrs, or Ͼ140 beats/minute if aged Ն5 yrs); hypoxia (oxygen saturation Ͻ95%); hypotension: and low systolic blood pressure (Ͻ70 mm Hg for Ͻ12 months and Ͻ80 mm Hg for Ͼ1 yr) or delayed capillary refill time (Ն3 secs).
Secondary end points included in-hospital mortality, resolution of acidosis (percentage reduction of base deficit by 8 hrs), potential complications of volume resuscitation such as pulmonary edema, raised intracranial pressure (systolic blood pressure of Ͼ90th centile for age in association with a falling heart rate, or papillodema, or brain stem features of transtentorial herniation [21] ), allergic reaction, and neurologic sequelae determined at discharge and 1 month following discharge by standardized neurologic assessment.
Sample Size
Our aim was to generate safety data regarding the use of these two colloids in children with severe malaria, and therefore the numbers required to address the trial objectives were balanced against minimizing the exposure of children to a therapeutic intervention for which there are no available data for severe malaria. Formal sample sizes were therefore not calculated. We aimed to recruit 80 children, 40 to receive Dextran and 40 to receive HES, which would give sufficient data on the frequency of serious adverse events and clinical data on the correction of hypovolemic shock. Our previous experience suggested that this number was sufficient to provide information on these key end points (3, 10, 15, 16) . Additional new data generated by the study included bolus volumes required of Dextran and HES to achieve satisfactory improvements in hemodynamic features of shock (primary end point). The trial had a design similar to that of previously published trials (3, 10, 15, 16) but differed in that children with decompensated shock (low systolic blood pressure) were excluded in the current trial, since ethical approval to defer consent for these cases, permitted in the previous studies, was declined. The ethics committee raised concerns over the safety of the Dextrans, which in a previous trial had resulted in acute febrile reactions (22) .
Randomization Procedure
Fluid interventions were randomly assigned using cards in presealed opaque envelopes indicating either Dextran or HES by the admitting clinician. A separate randomization was used for AQUAMAT trial. The randomization lists and envelopes for each trial were prepared separately and in advance of the each trial by an independent person not involved in recruitment, and the lists were not available to the investigators. Randomization cards were numbered consecutively and opened in numerical order. The intervention arms were not masked in either trial.
Statistical Analysis
The analyses conducted were by intention to treat. Primary and secondary outcome measures were compared between intervention arms. The primary end point (achievement of resuscitation targets) and secondary end points (death and adverse events) were compared using chi-square tests or Fisher's exact tests as appropriate. Base deficit reduction was examined at 8 hrs postadmission to determine the extent of resolution of acidosis.
We also compared the area under the curve and maximum value for repeated measures such as heart rate, base excess, systolic blood pressure, and respiratory rate between the two interventions according to the method of summary measures proposed by Matthews et al (23, 24) . We used these two summary measures to avoid any potential biases from missing observations at any time point.
RESULTS
The trial ran from June 2006 to December 2008. In total, 133 children were screened for trial eligibility, and 101 were eligible, 16 (16%) refused consent, and six were excluded for other reasons (see trial flow: Fig. 1 ). Eight emergencies did not qualify for the trial; seven were managed on 0.9% saline, and mortality was two in seven (2/7, 28.5%), whereas one child died before 0.9% saline infusion could be started. Seventy-nine children were enrolled; 39 to Dextran arm and 40 to with HES arm. The final envelope was inadvertently opened prematurely, since parental consent was withdrawn before enrolment. The median age of the trial participants was 40 months (interquartile range, 28 -53), with no statistically significant differences in the age or weight for the two intervention groups. Data from all the patients enrolled were analyzed.
Baseline Variables
Admission baseline clinical and laboratory features of the trial participants are shown in Table 1 . As an index of imbalance inherent within study groups in a small trial, we compared a priori risk factors by treatment arm and found very few differences. The exception was hypoglycemia, being slightly more common in children randomized to HES 12 (30%) compared to 5 (13%) receiving Dextran (p ϭ .09). At admission, 39 (50%) of cases were complicated by deep coma, 52 (65%) had deep breathing (a clinical sign of metabolic acidosis), and 50 (63%) had one or more signs of impaired perfusion, with no differences between the allocation arms. A total of 20 out of 79 (25%) children received blood transfusion per protocol after admission, 11 (28%) in the Dextran arm and nine (23%) in the HES arm (p ϭ .71).
Comorbidity
None of the children had microbiological evidence of sepsis, meningitis, or urinary tract infection, with the exception of one child, who was enrolled to the HES arm. The child had Streptococcus pneumoniae bacteremia and concurrent streptococcal meningitis. We found no evidence of neurologic sequelae arising from this admission at discharge or at follow-up.
Primary End Points
No differences were found in the proportions attaining resuscitation targets between the two intervention arms at either 4 or 8 hrs (Table 2) . At the 4-hr review, 25 out of 77 (32%) patients remained tachycardic but without other features of impaired perfusion, so further boluses were not prescribed. Eighteen children who had other features of impaired perfusion (capillary refill Ն3 s) at this time point received extra fluid boluses. Protocol was adhered to and volume expansion was adequate, including among those children who subsequently died. 
Secondary End Points
There were five (14%) adverse events out of 35 cases: four deaths (5%) and one (0.01%) neurologic sequela. Two deaths occurred in each arm of the study; three of the four fatalities occurred in the subgroup of children admitted in unrousable coma. The fourth case was a child admitted with marked agitation. Overall, mortality in the high-risk group (coma and metabolic acidosis) was low, at 8% (3/39): 11% (2/18) in the Dextran arm and 5% (1/21) in the HES arm.
The proportion of patients with persistent acidosis was significantly higher in the Dextran arm compared to the HES arm at both 4 and 8 hrs ( Table 2) . Children randomized to Dextran received a higher volume of bolus intervention as compared to HES, although this was nonsignificant ( Table 2 ). Fatal cases received higher volume of fluid expansion (mean 33 mL; SD 7) as compared to those who survived (mean 24 mL; SD 1) (p ϭ .04). There were no other serious adverse events reported. Specifically, we did not detect evidence of pulmonary edema, raised intracranial pressure, or allergic/ febrile events in any of the participants. We found no evidence of renal impairment, as measured by urinary output and serial plasma creatinine levels. Although coagulopathy or bleeding problems were not clinically apparent, we were not able to provide laboratory evidence to support this observation. At discharge and monthly follow-up, all trial participants were reviewed, including a detailed neurologic assessment. There were no deaths between the time of discharge and the 1-month follow-up. One child randomized to Dextran had a worsening of preexisting epilepsy at discharge and subsequent review.
Serial Measurements
There was a decrease in the mean heart rate with time in both study arms, with the greatest decline in the first 8 -10 hrs and steadier decline thereafter (Fig.  2) . Similarly, the mean respiratory rate decreased with time in both arms (Fig. 3) ; however, we noted the Dextran arm had relatively higher mean respiratory rate post recruitment than the HES arm. There was some evidence, albeit weak, of a difference in the area under the curve and maximum value of the serial respiratory rates between the two intervention arms (Wilcoxon rank sum, p ϭ .07 and p ϭ .06, respectively) ( Table 2) .
DISCUSSION
This trial extends our experience with colloidal resuscitation fluids in children with severe malaria. Both HES and Dextran appear to be safe in children with severe malaria complicated by acidosis, with minimal adverse events and a favorable outcome. Resolution of clinical features of shock was similar for both intervention arms. Mortality was low (5%) including children in the high-risk group (coma and acidosis: 8%) with no de novo neurologic complications following recovery. We noted some evidence of a better resolution of acidosis and a better resolution of respiratory distress in children receiving HES compared to Dex- n, number with specified outcome; N, total number including those with missing variables; HES, hydroxyethyl starch; CI, confidence interval; AUC, area under the curve; SBP, systolic blood pressure.
tran, but in the absence of any other superiority on outcome, this finding is of uncertain significance. This is the first trial to have generated safety and efficacy of these two fluids for treating children with severe malaria complicated by metabolic acidosis. As this is part of a series of studies involving fluid resuscitation directed at correcting shock, the results should be reviewed contextually with other trials involving patients randomized to colloids. In severe malaria, we have previously shown although HAS and Gelofusine (a gelatin) resulted in similar resolution of shock and acidosis, we demonstrated a superior survival benefit of children resuscitated using HAS when analyzed by intention to treat (15) . Previous trials comparing HAS to 0.9% saline also had similar findings in the intention to treat analysis (3, 10, 16) .
The low mortality (5%) observed in the current trial should be cautiously interpreted and may not be strictly comparable with overall mortality in our previous trials (Ϸ10%), although comparable to mortality in the HAS-treated groups (4%). No inference can be directly drawn about the superiority of either HES or Dextran over either saline or Gelofusine, since the current trial excluded children with hypotension, who were included in previous trials where consent was deferred for such children. We suggest that the cohort eligible for the current trial may have a lower a priori mortality. Nevertheless, the 92% intact survival of the high-risk group (coma and acidosis) and the minimal neurologic events (worsening of preexisting epilepsy in one patient) are reassuring and indicate that these colloids remain an attractive option for future clinical investigation.
We have not presented data on the effect of coenrolment into the AQUAMAT trial. The AQUAMAT trial is a large, ongoing, multicountry trial comparing two antimalarial drugs, quinine and artesunate, in over 5000 children with severe malaria. Owing to the different modes of action, there is no a priori evidence that might suggest an interaction with these study interventions with Dextran of HES nor is there any rationale to indicate the existence of one.
In dengue shock syndrome, children receiving HES were found to have less requirement for a rescue colloid and faster cardiovascular recovery when compared to those randomized to Dextran during the initial stages of shock (22) . These findings are also supported by a study in adults with severe sepsis (25) . The dengue trial reported some allergic or febrile reactions in children receiving Dextran, but no episodes of bleeding or laboratory evidence of worsening coagulopathy were reported in any of three arms. These findings are reassuring, especially for a condition where coagulopathy manifests in the pathophysiology, with respect to the long-standing fears about the increased risk of coagulopathy in patients receiving colloids. We did not find overt bleeding problems, and even though we were not able to measure microcoagulation abnormalities, the findings in dengue suggest that this may be unlikely.
We observed a faster resolution of the metabolic acidosis and respiratory distress in children receiving HES compared to Dextran. Simultaneous improvements of respiratory distress (a clinical marker of metabolic acidosis [6, 7] ) and laboratory measures of acidosis (base deficit) in HES suggest that this is unlikely to be a chance finding. Neither could the findings be explained by any differences in baseline characteristics at admission, which were similar in the two arms, but we interpret these findings only cautiously due the small size sample and the lack of benefit on overall outcome. The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis trial, comparing a medium-molecular-weight starch (HES 200/0.5), 10% pentastarch, and modified Ringer's lactate in adults with sepsis, reported an earlier normalization of central venous pressure/oxygen concentration in the pentastarch group. Nevertheless, the outcome in the pentastarch group was worse due to a higher number of dose-related episodes of renal failure (doubling of creatinine levels), requirement for renal replacement therapy, and poorer survival over a 90-day follow-up duration (26) . While concerns for safety of starches is not new (27) , recent evidence suggests that the newer generation of medium-molecular-weight starches such as HES 130/0.4 do not increase the incidence of acute renal failure (28 -30) . The higher-concentration (10%) starches have a higher waterbinding capacity and hence reduced renal flow (31) . In addition, the higher-molecular-weight pentastarch, but not the medium-molecular-weight starches, are incompletely metabolized and thus stored in the kidney, the mechanism thought to be responsible for acute renal damage (31, 32) . A meta-analysis concluded that starches in larger doses result in an increased incidence of acute renal failure and late death (33) . Our data suggest no evidence of a renal impairment over 24 hrs of observation, as its use was associated with falling creatinine levels and good urine output (Fig. 4) . However, the volumes prescribed in the current trial were modest and less liable to result in detrimental effects on renal function. Our experience has shown that hypovolemic shock in severe malaria is generally fluid responsive, an observation supported by recent studies examining cardiac function in children undergoing fluid resuscitation (34) . Nevertheless, further exploration of HES in future clinical trials should consider including longerterm monitoring of renal function and survival.
CONCLUSIONS
Fluid resuscitation in children with severe malaria using HES or Dextran appears safe and results in similar resolution of clinical features of shock. An ongoing multicenter trial comparing HAS to saline in African children with shock secondary to severe malaria and/or severe sepsis (FEAST ISRCTN; 69856593) may lead to major policy changes. If the results conclude that HAS is superior, then the results of this study support further exploration of either colloid in future trials.
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